123 related articles for article (PubMed ID: 24403494)
21. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
Kim SH; Kwon HC; Oh SY; Lee DM; Lee S; Lee JH; Roh MS; Kim DC; Park KJ; Choi HJ; Kim HJ
Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
[TBL] [Abstract][Full Text] [Related]
22. Clinical behaviors and outcomes for adenocarcinoma or adenosquamous carcinoma of cervix treated by radical hysterectomy and adjuvant radiotherapy or chemoradiotherapy.
Huang YT; Wang CC; Tsai CS; Lai CH; Chang TC; Chou HH; Lee SP; Hong JH
Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):420-7. PubMed ID: 22365621
[TBL] [Abstract][Full Text] [Related]
23. Impact of epidermal growth factor receptor expression on disease-free survival and rate of pelvic relapse in patients with advanced cancer of the cervix treated with chemoradiotherapy.
Pérez-Regadera J; Sánchez-Muñoz A; De-la-Cruz J; Ballestín C; Lora D; García-Martín R; Sotoca A; Pérez-Ruiz E; Lanzós E
Am J Clin Oncol; 2011 Aug; 34(4):395-400. PubMed ID: 20859196
[TBL] [Abstract][Full Text] [Related]
24. ERCC1 expression and tumor regression predict survival in esophageal squamous cell carcinoma patients receiving combined trimodality therapy.
Ge H; Lu Y; Chen Y; Zheng X; Wang W; Yu J
Pathol Res Pract; 2014 Oct; 210(10):656-61. PubMed ID: 25042384
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of excision repair cross-complementing gene 1 expression for cisplatin-based chemotherapy in advanced gastric cancer.
Ozkan M; Akbudak IH; Deniz K; Dikilitas M; Dogu GG; Berk V; Karaca H; Er O; Altinbas M
Asian Pac J Cancer Prev; 2010; 11(1):181-5. PubMed ID: 20593954
[TBL] [Abstract][Full Text] [Related]
26. Ten-year survival of patients with locally advanced, stage ib-iib cervical cancer after neoadjuvant chemotherapy and radical hysterectomy.
Hwang YY; Moon H; Cho SH; Kim KT; Moon YJ; Kim SR; Kim DS
Gynecol Oncol; 2001 Jul; 82(1):88-93. PubMed ID: 11426967
[TBL] [Abstract][Full Text] [Related]
27. Expression of DNA damage response proteins in cervical cancer patients treated with radical chemoradiotherapy.
Ho CK; Kornaga EN; Klimowicz AC; Enwere EK; Dean M; Bebb GD; Phan T; Ghatage P; Magliocco AM; Lees-Miller SP; Doll CM
Gynecol Oncol; 2017 Apr; 145(1):176-184. PubMed ID: 28131528
[TBL] [Abstract][Full Text] [Related]
28. High tumor interstitial fluid pressure identifies cervical cancer patients with improved survival from radiotherapy plus cisplatin versus radiotherapy alone.
Milosevic MF; Pintilie M; Hedley DW; Bristow RG; Wouters BG; Oza AM; Laframboise S; Hill RP; Fyles AW
Int J Cancer; 2014 Oct; 135(7):1692-9. PubMed ID: 23904154
[TBL] [Abstract][Full Text] [Related]
29. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
Vilmar A; Sørensen JB
Lung Cancer; 2009 May; 64(2):131-9. PubMed ID: 18804893
[TBL] [Abstract][Full Text] [Related]
30. Impact of ERCC1 expression on treatment outcome in small-cell lung cancer patients treated with platinum-based chemotherapy.
Sodja E; Knez L; Kern I; Ovčariček T; Sadikov A; Cufer T
Eur J Cancer; 2012 Dec; 48(18):3378-85. PubMed ID: 22795264
[TBL] [Abstract][Full Text] [Related]
31. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.
Cobo M; Isla D; Massuti B; Montes A; Sanchez JM; Provencio M; Viñolas N; Paz-Ares L; Lopez-Vivanco G; Muñoz MA; Felip E; Alberola V; Camps C; Domine M; Sanchez JJ; Sanchez-Ronco M; Danenberg K; Taron M; Gandara D; Rosell R
J Clin Oncol; 2007 Jul; 25(19):2747-54. PubMed ID: 17602080
[TBL] [Abstract][Full Text] [Related]
32. Molecular Markers for the Prediction of Minor Response to Neoadjuvant Chemoradiation in Esophageal Cancer: Results of the Prospective Cologne Esophageal Response Prediction (CERP) Study.
Bollschweiler E; Hölscher AH; Herbold T; Metzger R; Alakus H; Schmidt H; Drebber U; Warnecke-Eberz U
Ann Surg; 2016 Nov; 264(5):839-846. PubMed ID: 27741011
[TBL] [Abstract][Full Text] [Related]
33. Outcomes and prognostic factors of cervical cancer after concurrent chemoradiation.
Kim TE; Park BJ; Kwack HS; Kwon JY; Kim JH; Yoon SC
J Obstet Gynaecol Res; 2012 Nov; 38(11):1315-20. PubMed ID: 22612778
[TBL] [Abstract][Full Text] [Related]
34. The roles of excision repair cross-complementation group1 in objective response after cisplatin-based concurrent chemoradiotherapy and survival in head and neck cancers: a systematic review and meta-analysis.
Gao Y; Liu D
Oral Oncol; 2015 Jun; 51(6):570-7. PubMed ID: 25857670
[TBL] [Abstract][Full Text] [Related]
35. The role of completion surgery after concurrent radiochemotherapy in locally advanced stages IB2-IIB cervical cancer.
Chereau E; DE LA Hosseraye C; Ballester M; Monnier L; Rouzier R; Touboul E; Daraï E
Anticancer Res; 2013 Apr; 33(4):1661-6. PubMed ID: 23564812
[TBL] [Abstract][Full Text] [Related]
36. ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation.
Jun HJ; Ahn MJ; Kim HS; Yi SY; Han J; Lee SK; Ahn YC; Jeong HS; Son YI; Baek JH; Park K
Br J Cancer; 2008 Jul; 99(1):167-72. PubMed ID: 18594541
[TBL] [Abstract][Full Text] [Related]
37. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation.
Azuma K; Sasada T; Kawahara A; Hattori S; Kinoshita T; Takamori S; Ichiki M; Imamura Y; Ikeda J; Kage M; Kuwano M; Aizawa H
Cancer Chemother Pharmacol; 2009 Aug; 64(3):565-73. PubMed ID: 19123003
[TBL] [Abstract][Full Text] [Related]
38. ERCC1 mRNA levels can predict the response to cisplatin-based concurrent chemoradiotherapy of locally advanced cervical squamous cell carcinoma.
Bai ZL; Wang YY; Zhe H; He JL; Hai P
Radiat Oncol; 2012 Dec; 7():221. PubMed ID: 23259415
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of ERCC1 expression for cisplatin sensitivity in human hepatocellular carcinoma.
Ueda S; Shirabe K; Morita K; Umeda K; Kayashima H; Uchiyama H; Soejima Y; Taketomi A; Maehara Y
Ann Surg Oncol; 2011 Apr; 18(4):1204-11. PubMed ID: 21076943
[TBL] [Abstract][Full Text] [Related]
40. Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy.
Ronchi CL; Sbiera S; Kraus L; Wortmann S; Johanssen S; Adam P; Willenberg HS; Hahner S; Allolio B; Fassnacht M
Endocr Relat Cancer; 2009 Sep; 16(3):907-18. PubMed ID: 19240185
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]